Cargando…
Investigating Colorimetric Protein Array Assay Schemes for Detection of Recurrence of Bladder Cancer
A colorimetric microarray for the multiplexed detection of recurrence of bladder cancer including protein markers interleukin-8 (IL8), decorin (DCN), and vascular endothelial growth factor (VEGF) was established to enable easy and cheap read-out by a simple office scanner paving the way for quick th...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5872058/ https://www.ncbi.nlm.nih.gov/pubmed/29364182 http://dx.doi.org/10.3390/bios8010010 |
_version_ | 1783309753973211136 |
---|---|
author | Gogalic, Selma Sauer, Ursula Doppler, Sara Preininger, Claudia |
author_facet | Gogalic, Selma Sauer, Ursula Doppler, Sara Preininger, Claudia |
author_sort | Gogalic, Selma |
collection | PubMed |
description | A colorimetric microarray for the multiplexed detection of recurrence of bladder cancer including protein markers interleukin-8 (IL8), decorin (DCN), and vascular endothelial growth factor (VEGF) was established to enable easy and cheap read-out by a simple office scanner paving the way for quick therapy monitoring at doctors’ offices. The chip is based on the principle of a sandwich immunoassay and was optimized prior to multiplexing using IL8 as a model marker. Six different colorimetric assay formats were evaluated using a detection antibody (dAB) labeled with (I) gold (Au) nanoparticles (NPs), (II) carbon NPs, (III) oxidized carbon NPs, and a biotinylated dAB in combination with (IV) neutravidin–carbon, (V) streptavidin (strp)–gold, and (VI) strp–horseradish peroxidase (HRP). Assay Format (III) worked best for NP-based detection and showed a low background while the enzymatic approach, using 3,3′,5,5′-tetramethylbenzidine (TMB) substrate, led to the most intense signals with good reproducibility. Both assay formats showed consistent spot morphology as well as detection limits lower than 15 ng/L IL8 and were thus applied for the multiplexed detection of IL8, DCN, and VEGF in synthetic urine. Colorimetric detection in urine (1:3) yields reaction signals and measurement ranges well comparable with detection in the assay buffer, as well as excellent data reproducibility as indicated by the coefficient of variation (CV 5–9%). |
format | Online Article Text |
id | pubmed-5872058 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-58720582018-03-29 Investigating Colorimetric Protein Array Assay Schemes for Detection of Recurrence of Bladder Cancer Gogalic, Selma Sauer, Ursula Doppler, Sara Preininger, Claudia Biosensors (Basel) Article A colorimetric microarray for the multiplexed detection of recurrence of bladder cancer including protein markers interleukin-8 (IL8), decorin (DCN), and vascular endothelial growth factor (VEGF) was established to enable easy and cheap read-out by a simple office scanner paving the way for quick therapy monitoring at doctors’ offices. The chip is based on the principle of a sandwich immunoassay and was optimized prior to multiplexing using IL8 as a model marker. Six different colorimetric assay formats were evaluated using a detection antibody (dAB) labeled with (I) gold (Au) nanoparticles (NPs), (II) carbon NPs, (III) oxidized carbon NPs, and a biotinylated dAB in combination with (IV) neutravidin–carbon, (V) streptavidin (strp)–gold, and (VI) strp–horseradish peroxidase (HRP). Assay Format (III) worked best for NP-based detection and showed a low background while the enzymatic approach, using 3,3′,5,5′-tetramethylbenzidine (TMB) substrate, led to the most intense signals with good reproducibility. Both assay formats showed consistent spot morphology as well as detection limits lower than 15 ng/L IL8 and were thus applied for the multiplexed detection of IL8, DCN, and VEGF in synthetic urine. Colorimetric detection in urine (1:3) yields reaction signals and measurement ranges well comparable with detection in the assay buffer, as well as excellent data reproducibility as indicated by the coefficient of variation (CV 5–9%). MDPI 2018-01-24 /pmc/articles/PMC5872058/ /pubmed/29364182 http://dx.doi.org/10.3390/bios8010010 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Gogalic, Selma Sauer, Ursula Doppler, Sara Preininger, Claudia Investigating Colorimetric Protein Array Assay Schemes for Detection of Recurrence of Bladder Cancer |
title | Investigating Colorimetric Protein Array Assay Schemes for Detection of Recurrence of Bladder Cancer |
title_full | Investigating Colorimetric Protein Array Assay Schemes for Detection of Recurrence of Bladder Cancer |
title_fullStr | Investigating Colorimetric Protein Array Assay Schemes for Detection of Recurrence of Bladder Cancer |
title_full_unstemmed | Investigating Colorimetric Protein Array Assay Schemes for Detection of Recurrence of Bladder Cancer |
title_short | Investigating Colorimetric Protein Array Assay Schemes for Detection of Recurrence of Bladder Cancer |
title_sort | investigating colorimetric protein array assay schemes for detection of recurrence of bladder cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5872058/ https://www.ncbi.nlm.nih.gov/pubmed/29364182 http://dx.doi.org/10.3390/bios8010010 |
work_keys_str_mv | AT gogalicselma investigatingcolorimetricproteinarrayassayschemesfordetectionofrecurrenceofbladdercancer AT sauerursula investigatingcolorimetricproteinarrayassayschemesfordetectionofrecurrenceofbladdercancer AT dopplersara investigatingcolorimetricproteinarrayassayschemesfordetectionofrecurrenceofbladdercancer AT preiningerclaudia investigatingcolorimetricproteinarrayassayschemesfordetectionofrecurrenceofbladdercancer |